Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B5LF
|
|||
| Former ID |
DAP001537
|
|||
| Drug Name |
Ximelegatran
|
|||
| Synonyms |
Cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; y-27632; 146986-50-7; Y-27632 dihydrochloride; Y27632; UNII-0X370ROP6H; Y 27632; cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; 0X370ROP6H; CHEBI:75393; 4-[(1R)-1-aminoethyl]-N-(pyridin-4-yl)cyclohexane-1-carboxamide; (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE; 4-[(1R)-1-aminoethyl]-N-(4-pyridyl)cyclohexanecarboxamide; 4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide; (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide; Y-27632
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Myocardial infarction [ICD-11: BA41-BA43] | Approved | [1] | |
| Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Terminated | [2], [3] | ||
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H21N3O
|
|||
| Canonical SMILES |
CC(C1CCC(CC1)C(=O)NC2=CC=NC=C2)N
|
|||
| InChI |
1S/C14H21N3O/c1-10(15)11-2-4-12(5-3-11)14(18)17-13-6-8-16-9-7-13/h6-12H,2-5,15H2,1H3,(H,16,17,18)/t10-,11?,12?/m1/s1
|
|||
| InChIKey |
IYOZTVGMEWJPKR-VOMCLLRMSA-N
|
|||
| CAS Number |
CAS 146986-50-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
830156, 841201, 7891193, 8028485, 11120129, 11120617, 11121105, 11121802, 11122282, 11147212, 11362988, 11365550, 11368112, 11371127, 11371128, 11373713, 11376274, 11532694, 11532697, 14798541, 14847630, 17422547, 26753164, 26753165, 34932925, 36890023, 46392966, 46394059, 46394196, 46394199, 46514394, 47216599, 47365003, 47440057, 48034921, 48259041, 50074632, 50105663, 50105664, 53787296, 57404850, 80086449, 85787251, 85787299, 90340876, 92310153, 99301065, 99302585, 99437221, 99445227
|
|||
| ChEBI ID |
CHEBI:75393
|
|||
| SuperDrug ATC ID |
B01AE05
|
|||
| SuperDrug CAS ID |
cas=192939461
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5290). | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010598) | |||
| REF 4 | Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83. | |||
| REF 5 | Molecular characterization of the effects of Y-27632. Cell Motil Cytoskeleton. 2007 Feb;64(2):97-109. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.